Syneos Health to Implement MRD Assessment in Solid Tumor Clinical Trials, Utilizing NTRA's Signatera and Other Technologies
1. Evolution of MRD's Clinical Role
Minimal Residual Disease (MRD) is evolving from a simple prognostic indicator to a key trigger that directly determines therapeutic intervention. Previously, it was used to confirm the presence of residual cancer cells after treatment; now, this data can be used to conduct personalized treatment from the early stages of new drug development. In particular, in solid tumor clinical trials, early detection of subtle tumor signals improves treatment efficacy and reduces unnecessary drug exposure, protecting patient safety. This change is becoming a critical milestone that determines the success of new drug development pipelines and the planning of clinical trials.
2. Significant Shift in Regulatory Agency Stance and Accelerated Approvals
The global regulatory agency, the U.S. Food and Drug Administration (FDA), has begun to recognize MRD data as an official surrogate endpoint in clinical evaluations. On April 12, 2024, the FDA's Oncologic Drugs Advisory Committee (ODAC) unanimously approved (12-0) the use of MRD as a surrogate endpoint for accelerated approval in multiple myeloma clinical trials. In early 2026, a draft guidance to support this will be released, completing the institutional framework for accelerating new drug development. This is a key change that will drastically reduce the years of waiting time required to track the survival rate of new drug candidates.
3. Expansion into Solid Tumors and Innovative Design
The MRD analysis method, which has been successful in hematological malignancies, is now being actively incorporated into various solid tumor clinical protocols, including breast cancer, colorectal cancer, and head and neck cancer. The global pharmaceutical and biotechnology industry is breaking down the traditional boundaries of Phase 1 to Phase 3 trials and adopting adaptive trial designs, in which drug administration is strengthened or stopped based on the dynamic changes in MRD. This innovative design provides a basis for maximizing the therapeutic efficacy of drugs by monitoring the prognosis of clinical trial participants in real-time. However, to successfully conduct global, multinational clinical trials, it is essential to have sophisticated operational capabilities to reduce inter-country variations in sample analysis and ensure data consistency.
4. High-Growth Market and Co-Growth of Diagnostic Companies
The global MRD testing market is expected to grow rapidly to at least USD$2.39 billion to USD$4.5 billion by 2030, with a compound annual growth rate (CAGR) of approximately 8.7% to 14.8%. Thanks to this strong market potential, the corporate value of diagnostic platform companies with liquid biopsy technology is also increasing. Natera (NTRA)'s 'Signatera,' Guardant Health (GH)'s 'Guardant Reveal,' and Adaptive Biotechnologies (ADPT)'s 'clonoSEQ' have become standard platforms in clinical practice. Global contract research organizations (CROs) such as Syneos Health, which combine these diagnostic technologies to provide efficient clinical solutions, are also attracting industry attention.
In the short term, the use of MRD data in the early stages (Phase 1/2) of clinical trials to select treatment groups will generate economic benefits by reducing clinical costs by more than 20% and significantly shortening the development period. In the medium to long term, the FDA ODAC's unanimous approval of MRD as a surrogate endpoint in multiple myeloma will expand to solid tumors, which will be an opportunity to re-evaluate the value of ctDNA analysis platform companies such as Natera (NTRA)'s 'Signatera' and Guardant Health (GH)'s 'Guardant Reveal.' From a researcher's perspective, it will be possible to diversify protocols with adaptive designs based on MRD response, moving away from simple survival tracking, to maximize therapeutic efficacy and rapidly demonstrate the mechanism of action (MoA). From the perspective of industry professionals and investors, it is important to focus on the long-term potential of the global MRD diagnostics market, which is expected to grow to USD$4.5 billion by 2030 with an annual growth rate of 14.8%, and the accompanying partnership opportunities with major pharmaceutical companies.